Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results

American Journal of Ophthalmology

Volumn 147, Issue 1, 2009, Pages

  Gharbiya, Magda ^a   Allievi, Francesca ^a   Mazzeo, Luigi ^a   Gabrieli, Corrado Balacco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUORESCEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA FOVEA; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 57549110464     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.07.022     Document Type: Article

References (36)

1. Yoshida T., Ohno-Matsui K., Yasuzumi K., et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110 (2003) 1297-1305
2. Ohno-Matsui K., Yoshida T., Futagami S., et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularization in pathologic myopia. Br J Ophthalmol 87 (2003) 570-573
3. Chan W.M., Ohji M., Lai T.Y.Y., Liu D.T.L., Tano Y., and Lam D.S.C. Choroidal neovascularization in pathological myopia: an update management. Br J Ophthalmol 89 (2005) 1522-1528
4. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial: VIP Report No. 1. Ophthalmology 108 (2001) 841-852
5. Chan W.M., Lai T.Y.Y., Wong A.L., Liu D.T.L., and Lam D.S.C. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 91 (2007) 174-179
6. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresss choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 89 (2005) 1368-1370
7. Sadda S.R., Wu Z., Walsh A.C., et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 113 (2006) 285-293
8. Blinder K.J., Blumenkranz M.S., Bressler N.M., et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report No. 3. Ophthalmology 110 (2003) 667-673
9. Shahar J., Avery R.L., Heilweil G., et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26 (2006) 262-269
10. Emerson M.V., Lauer A.K., Flaxel C.J., et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27 (2007) 439-444
11. Goff M.J., Johnson R.N., McDonald H.R., et al. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 27 (2007) 432-438
12. Lazic R., and Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 245 (2007) 68-73
13. Costa R.A., Jorge R., Calucci D., et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 47 (2006) 4569-4578
14. Spaide R.F., Laud K., Fine H.F., et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
15. Inan U.U., Avci B., Kusbeci T., et al. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48 (2007) 1773-1781
16. Feiner L., Barr E.E., Shui Y.B., Holekamp N.M., et al. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26 (2006) 882-888
17. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
18. Luke M., Warga M., Ziemssen F., et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90 (2006) 1178-1182
19. Luthra S., Narayanan R., Marques L.E., et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26 (2006) 512-518
20. Maturi R.K., Bleau L.A., and Wilson D.L. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26 (2006) 270-274
21. Manzano R.P., Peyman G.A., Khan P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 (2006) 257-261
22. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathologic myopia. Br J Ophthalmol 91 (2007) 157-160
23. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularization associated with pathological myopia. Br J Ophthalmol 91 (2007) 161-165
24. Laud K., Spaide R.F., Freund K.B., et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 26 (2006) 960-963
25. Hernandez-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 27 (2007) 707-712
26. Chan W.M., Lai T.Y.Y., Liu D.T.L., and Lam D.S.C. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization. Six months results of a prospective pilot study. Ophthalmology 114 (2007) 2190-2196
27. Delori F.C., Goger D.G., and Dorey C.K. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci 42 (2001) 1855-1866
28. Axer-Siegel R., Ehrilch R., Weinberger D., et al. Photodynamic therapy of subfoveal choridal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 138 (2004) 602-607
29. Yoshida T., Ohno-matsui K., Ohtake Y., et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 109 (2002) 712-719
30. Kojima A., Ohno-Matsui K., Teramukai S., et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefe's Arch Clin Exp Ophthalmol 244 (2006) 1474-1479
31. Axer-Siegel R., Ehrlich R., Weinberger D., et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age. Am J Ophthalmol 138 (2004) 602-607
32. Ergun E., Heinzl H., and Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 138 (2004) 434-438
33. Montero J.A., and Ruiz Moreno J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularization. Br J Ophthalmol 87 (2003) 173-176
34. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
35. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
36. Antoszyk A.N., Tuomi L., Chung C.Y., Singh A., and FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 145 (2008) 862-874